<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Model parameters and Sources</p>
 </caption>
 <table frame="hsides" rules="groups">
  <tbody>
   <tr>
    <td colspan="5">
     <bold>Calibration Data</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Calibrated parameter</bold>
    </td>
    <td colspan="4">
     <bold>Value and Source</bold>
    </td>
   </tr>
   <tr>
    <td>Number of diagnosed and in care HIV-infected and chronic HCV coinfected (HIV+/HCV+) in 2015</td>
    <td colspan="4">3075 as observed in the HERACLES cohort [
     <xref ref-type="bibr" rid="CR17">17</xref>], with 2669 [range 2402–2936] with a history of PWID
    </td>
   </tr>
   <tr>
    <td>HCV chronic prevalence among PWID injecting for &lt; 10 years in 2010</td>
    <td colspan="4">45% [sampled uniformly from 40 to 50%]. Values from Folch et al. [
     <xref ref-type="bibr" rid="CR29">29</xref>], adjusted for weighted spontaneous clearance given HIV coinfection prevalence and spontaneous clearance rates by HIV-status in the below table.
    </td>
   </tr>
   <tr>
    <td>HCV chronic prevalence among PWID injecting for &gt; 10 years in 2010</td>
    <td colspan="4">60% [sampled uniformly from 55 to 65%] Values taken from Folch et al. [
     <xref ref-type="bibr" rid="CR29">29</xref>], adjusted for weighted spontaneous clearance given HIV coinfection prevalence and spontaneous clearance rates by HIV-status in the below table.
    </td>
   </tr>
   <tr>
    <td>HIV prevalence among PWID injecting for &lt;10 years, in 2010</td>
    <td colspan="4">20% [sampled uniformly from 10 to 30%] Values from Folch et al. [
     <xref ref-type="bibr" rid="CR29">29</xref>]
    </td>
   </tr>
   <tr>
    <td>HIV prevalence among PWID injecting for &gt; 10 years in 2010</td>
    <td colspan="4">40% [sampled uniformly 30–50%]. Values from Folch et al. [
     <xref ref-type="bibr" rid="CR29">29</xref>]
    </td>
   </tr>
   <tr>
    <td>HCV chronic prevalence among HIV+ ever PWID in 2015</td>
    <td colspan="4">54% [sampled uniformly 50–58%] [
     <xref ref-type="bibr" rid="CR18">18</xref>]
    </td>
   </tr>
   <tr>
    <td>Proportion of HIV+/HCV+ diagnosed individuals who are current PWID in 2015</td>
    <td colspan="4">14% [sampled uniformly 10–18%] as observed in the HERACLES cohort [
     <xref ref-type="bibr" rid="CR17">17</xref>]
    </td>
   </tr>
   <tr>
    <td>Proportion HIV+/HCV+ diagnosed ever PWID who had previously failed HCV treatment in 2015</td>
    <td colspan="4">32% [sampled uniformly 30–34%] as observed in the HERACLES cohort [
     <xref ref-type="bibr" rid="CR17">17</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="5">
     <bold>General Parameters</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Parameter Definition</bold>
    </td>
    <td>
     <bold>Symbol</bold>
    </td>
    <td>
     <bold>Sampled Value and 95% Interval</bold>
    </td>
    <td>
     <bold>Sampling Distribution</bold>
    </td>
    <td>
     <bold>Source</bold>
    </td>
   </tr>
   <tr>
    <td>Sustained HCV viral response, monoinfected on DAAs</td>
    <td>1- 
     <italic>f</italic>
     <sub>
      <italic>md</italic>
     </sub>
    </td>
    <td>0.9</td>
    <td/>
    <td>[
     <xref ref-type="bibr" rid="CR2">2</xref>]
    </td>
   </tr>
   <tr>
    <td>Sustained HCV viral response, coinfected on DAAs</td>
    <td>1- 
     <italic>f</italic>
     <sub>
      <italic>cd</italic>
     </sub>
    </td>
    <td>0.948</td>
    <td/>
    <td>HERACULES cohort</td>
   </tr>
   <tr>
    <td>Sustained HCV viral response, monoinfected pre-DAAs</td>
    <td>1- 
     <italic>f</italic>
     <sub>
      <italic>mpd</italic>
     </sub>
    </td>
    <td>0.52 (0.45–0.60)</td>
    <td>Uniform [0.45–0.60]</td>
    <td>Pooled SVR weighted by genotype and genotype distribution [
     <xref ref-type="bibr" rid="CR30">30</xref>, 
     <xref ref-type="bibr" rid="CR31">31</xref>].
    </td>
   </tr>
   <tr>
    <td>Sustained HCV viral response, coinfected pre-DAAs</td>
    <td>1- 
     <italic>f</italic>
     <sub>
      <italic>cpd</italic>
     </sub>
    </td>
    <td>0.30 (0.20.-0.39)</td>
    <td>Uniform [0.20–0.40]</td>
    <td>Pooled SVR weighted by genotype and genotype distribution [
     <xref ref-type="bibr" rid="CR30">30</xref>, 
     <xref ref-type="bibr" rid="CR32">32</xref>].
    </td>
   </tr>
   <tr>
    <td>Excess death rate due to mono-infection with HIV untreated per year</td>
    <td>μ
     <sub>uHIV</sub>
    </td>
    <td>0.097 (0.09–0.10)</td>
    <td>Uniform [1/9.6–1/11.5]</td>
    <td>[
     <xref ref-type="bibr" rid="CR33">33</xref>]
    </td>
   </tr>
   <tr>
    <td>Decreased mortality hazard ratio for HIV on ART</td>
    <td>μ
     <sub>HIV</sub>
    </td>
    <td>0.26 (0.20–0.32)</td>
    <td>Uniform [1/5–1/3]</td>
    <td>[
     <xref ref-type="bibr" rid="CR34">34</xref>, 
     <xref ref-type="bibr" rid="CR35">35</xref>]
    </td>
   </tr>
   <tr>
    <td>Excess death rate due to chronic HCV mono-infection per year</td>
    <td>μ
     <sub>HCV</sub>
    </td>
    <td>0.00169 (0.0016–0.00181)</td>
    <td>Uniform [0.00154–0.00183]</td>
    <td>[
     <xref ref-type="bibr" rid="CR36">36</xref>]
    </td>
   </tr>
   <tr>
    <td>Relative risk of death due to chronic HCV for HIV/HCV coinfection not on HIV treatment compared to HCV monoinfection</td>
    <td>RR
     <sub>_co_noART</sub>
    </td>
    <td>2.58 (1.70–3.99)</td>
    <td>Lognormal, from distribution 2.5 (95%CI 1.8–3.4)</td>
    <td>[
     <xref ref-type="bibr" rid="CR36">36</xref>, 
     <xref ref-type="bibr" rid="CR37">37</xref>]
    </td>
   </tr>
   <tr>
    <td>Excess death rate due to HCV for HIV-HCV co-infection with no HIV treatment per year</td>
    <td>μ
     <sub>HCVuHIV</sub>
    </td>
    <td>0.0042 (0.0039–0.0046)</td>
    <td>Uniform [0.0038–0.0046]</td>
    <td>[
     <xref ref-type="bibr" rid="CR36">36</xref>, 
     <xref ref-type="bibr" rid="CR37">37</xref>]
    </td>
   </tr>
   <tr>
    <td>Relative risk of death due to chronic HCV for HIV/HCV coinfection on HIV treatment compared to HIV/HCV coinfection no HIV treatment</td>
    <td>RR
     <sub>_coART</sub>
    </td>
    <td/>
    <td>0.68</td>
    <td>[
     <xref ref-type="bibr" rid="CR36">36</xref>, 
     <xref ref-type="bibr" rid="CR37">37</xref>]
    </td>
   </tr>
   <tr>
    <td>Excess death rate due to HIV for HIV-HCV co-infection with no HIV treatment per year</td>
    <td>μ
     <sub>uHIVHCV</sub>
    </td>
    <td>0.0005 (0.00041–0.00066)</td>
    <td>Uniform [0.0004–0.00069]</td>
    <td>[
     <xref ref-type="bibr" rid="CR36">36</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="5">PWID parameters</td>
   </tr>
   <tr>
    <td>Inflow of new PWID per year</td>
    <td>
     <italic>θ</italic>
    </td>
    <td/>
    <td/>
    <td>Deaths replaced, rate is halved in 2011. See text for discussion.</td>
   </tr>
   <tr>
    <td>Population size of active PWID in 2010</td>
    <td/>
    <td>7,500 (5,000-10,000)</td>
    <td>Uniform [5,000-10,000]</td>
    <td>8.4 million Andalusia population in 2010, 92% &gt; age 15, and a PWID prevalence among adults of 0.1% (national estimate) [
     <xref ref-type="bibr" rid="CR38">38</xref>, 
     <xref ref-type="bibr" rid="CR39">39</xref>],
    </td>
   </tr>
   <tr>
    <td>HCV treatment rate among PWID who are HIV- or HIV+ and undiagnosed (%/year)</td>
    <td>
     <italic>r</italic>, 
     <italic>r</italic>
     <sub>
      <italic>hu</italic>
     </sub>
    </td>
    <td>0.99% (0.54–1.44%)</td>
    <td>
     <p>Uniform</p>
     <p>[0.5–1.5%]</p>
    </td>
    <td>Assumed similar to estimates worldwide [
     <xref ref-type="bibr" rid="CR40">40</xref>]
    </td>
   </tr>
   <tr>
    <td>HCV treatment rate among HIV+ diagnosed individuals prior to 2015 (%/year)</td>
    <td>
     <italic>r</italic>
     <sub>
      <italic>hd</italic>
     </sub>
    </td>
    <td>Calibrated</td>
    <td/>
    <td>Calibrated to fit HERACLES data on proportion previously failed treatment in 2015</td>
   </tr>
   <tr>
    <td>HCV treatment rate among HIV+ diagnosed individuals from 2015 to 2020 (%/year)</td>
    <td>
     <italic>r</italic>
     <sub>
      <italic>hd</italic>
     </sub>
    </td>
    <td>33%</td>
    <td/>
    <td>HERACLES cohort (
     <italic>unpublished data from 2015 to 2017)</italic>
    </td>
   </tr>
   <tr>
    <td>Average duration of injecting until final cessation (years)</td>
    <td>1/μ
     <sub>cd</sub>
    </td>
    <td>15.1 (6.8–24.4)</td>
    <td>
     <p>Uniform</p>
     <p>[5–25]</p>
    </td>
    <td>Uncertain, so vary widely [
     <xref ref-type="bibr" rid="CR41">41</xref>, 
     <xref ref-type="bibr" rid="CR42">42</xref>]
    </td>
   </tr>
   <tr>
    <td>Background mortality rate per year among PWID</td>
    <td>μ</td>
    <td>0.0179</td>
    <td/>
    <td>Average life expectancy in Spain to 80.7 (WHO life table), and average age of injecting initiation age of 25 [
     <xref ref-type="bibr" rid="CR43">43</xref>]
    </td>
   </tr>
   <tr>
    <td>Overdose mortality rate among PWID per year</td>
    <td>μ
     <sub>IDU</sub>
    </td>
    <td>0.0062 (0.005–0.007)</td>
    <td>Uniform [0.0053–0.0070]</td>
    <td>[
     <xref ref-type="bibr" rid="CR44">44</xref>]
    </td>
   </tr>
   <tr>
    <td>Relative risk of HIV transmission through sex for those on ART</td>
    <td>RR
     <sub>HIVs</sub>
    </td>
    <td>0.107 (0.03–0.198)</td>
    <td>Lognormal [95% CI 0.01–0.27]</td>
    <td>[
     <xref ref-type="bibr" rid="CR45">45</xref>]
    </td>
   </tr>
   <tr>
    <td>Relative risk of HIV transmission through injecting for those on ART</td>
    <td>RR
     <sub>HIVi</sub>
    </td>
    <td>0.50 (0.27–0.72)</td>
    <td>
     <p>Uniform</p>
     <p>[0.25–0.75]</p>
    </td>
    <td>Limited data. One modeling study in Vancouver estimated 44% efficacy for preventing injecting transmission [
     <xref ref-type="bibr" rid="CR5">5</xref>] but uncertainty was wide.
    </td>
   </tr>
   <tr>
    <td>Relative risk of HCV transmission if HIV positive undiagnosed (off ART) compared to HIV negative</td>
    <td>RR
     <sub>HCV_ifHIVpos</sub>
    </td>
    <td>2 (1.2–2.8)</td>
    <td>Uniform [1–3]</td>
    <td>[
     <xref ref-type="bibr" rid="CR46">46</xref>, 
     <xref ref-type="bibr" rid="CR47">47</xref>]
    </td>
   </tr>
   <tr>
    <td>Annual probability of HIV transmission through sex during the latent untreated stage of infection</td>
    <td>β
     <sub>HIVs</sub> = 1/6* β
     <sub>HCV</sub>
    </td>
    <td/>
    <td/>
    <td>[
     <xref ref-type="bibr" rid="CR21">21</xref>]
    </td>
   </tr>
   <tr>
    <td>Proportion spontaneous HCV clearance among HIV negatives</td>
    <td>∆
     <sub>n</sub>
    </td>
    <td>0.25 (0.22–0.29)</td>
    <td>Uniform [0.22–0.29]</td>
    <td>[
     <xref ref-type="bibr" rid="CR48">48</xref>]
    </td>
   </tr>
   <tr>
    <td>Relative risk of spontaneous clearance among HIV positives compared to HIV negatives</td>
    <td>RR
     <sup>sponclearHIVpos</sup>
    </td>
    <td>0.68 (0.39–0.90)</td>
    <td>Lognormal [0.46–1.0]</td>
    <td>[
     <xref ref-type="bibr" rid="CR49">49</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="5">MSM parameters</td>
   </tr>
   <tr>
    <td>Number of HIV/HCV coinfected and diagnosed MSM in 2015</td>
    <td/>
    <td>406</td>
    <td/>
    <td>HERACLES cohort (
     <italic>unpublished)</italic>
    </td>
   </tr>
   <tr>
    <td>Number of newly HIV/HCV coinfected and diagnosed MSM each year</td>
    <td/>
    <td>Calculated</td>
    <td/>
    <td>Based on multiplying the number of HIV-infected MSM in 2010 by the proportion of HIV+ MSM who are diagnosed, by the primary HCV incidence among HIV-infected MSM.</td>
   </tr>
   <tr>
    <td>Number of HIV-infected MSM in 2010</td>
    <td>
     <italic>θ</italic>
     <sub>
      <italic>MSM</italic>
     </sub>
    </td>
    <td>16,281 (9,018–23,526)</td>
    <td>
     <p>Uniform</p>
     <p>[8,646-23,913]</p>
    </td>
    <td>
     <p>[
      <xref ref-type="bibr" rid="CR50">50</xref>–
      <xref ref-type="bibr" rid="CR52">52</xref>]
     </p>
     <p>Based on multiplying the male population over 15 years of age by the prevalence of MSM, and the prevalence of HIV-infected MSM in 2010</p>
    </td>
   </tr>
   <tr>
    <td>Proportion of HIV+ MSM who are diagnosed</td>
    <td/>
    <td>0.761 (0.751–0.771)</td>
    <td>
     <p>Uniform</p>
     <p>[0.75–0.772]</p>
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR53">53</xref>]
    </td>
   </tr>
   <tr>
    <td>Primary HCV incidence among HIV-infected MSM (per 100 person-years)</td>
    <td/>
    <td>1.17 (0.75–1.16)</td>
    <td>
     <p>Uniform</p>
     <p>[0.73–1.61]</p>
    </td>
    <td>
     <p>[
      <xref ref-type="bibr" rid="CR54">54</xref>]
     </p>
     <p>See 
      <xref rid="MOESM1" ref-type="media">supplement</xref> for details.
     </p>
    </td>
   </tr>
   <tr>
    <td>HCV reinfection incidence among HIV+ MSM (per 100 person-years)</td>
    <td>Γ</td>
    <td>7.07 (3.87–10.27)</td>
    <td>
     <p>Uniform</p>
     <p>[3.7–10.44]</p>
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR55">55</xref>]
    </td>
   </tr>
   <tr>
    <td>Background (non HIV or HCV) mortality rate among HIV/HCV-diagnosed MSM (per year)</td>
    <td>μ
     <sub>MSM</sub>
    </td>
    <td>0.026</td>
    <td/>
    <td>Average life expectancy in Spain of 80.7 [
     <xref ref-type="bibr" rid="CR56">56</xref>], and average age at HIV/HCV diagnosis of 43 [
     <xref ref-type="bibr" rid="CR57">57</xref>].
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
